Pediatrix Medical Group (NYSE:MD) Price Target Raised to $16.00

Pediatrix Medical Group (NYSE:MD) had its price objective boosted by Truist Financial from $13.00 to $16.00 in a research note published on Monday, Benzinga reports. They currently have a hold rating on the stock.

A number of other analysts also recently weighed in on MD. Mizuho upped their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Jefferies Financial Group raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their price objective for the company from $8.00 to $14.00 in a research note on Thursday, September 26th. Finally, UBS Group increased their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research note on Friday, August 9th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Trading Up 4.6 %

Shares of NYSE:MD opened at $16.06 on Monday. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $16.41. The stock has a market capitalization of $1.38 billion, a PE ratio of -5.25, a price-to-earnings-growth ratio of 2.35 and a beta of 1.55. The company’s 50-day moving average price is $11.89 and its two-hundred day moving average price is $9.54. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter in the prior year, the business posted $0.29 EPS. The business’s revenue was up .9% compared to the same quarter last year. On average, equities analysts forecast that Pediatrix Medical Group will post 1.19 EPS for the current fiscal year.

Insider Activity

In other news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO C Marc Richards sold 17,438 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $10.08, for a total transaction of $175,775.04. Following the completion of the sale, the chief financial officer now directly owns 175,347 shares in the company, valued at $1,767,497.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO James D. Swift sold 11,100 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 68,100 shares of company stock valued at $701,889. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Several large investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Pediatrix Medical Group in the second quarter worth $31,000. Innealta Capital LLC acquired a new stake in Pediatrix Medical Group in the second quarter worth $33,000. Nisa Investment Advisors LLC grew its holdings in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the period. CWM LLC grew its holdings in Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after purchasing an additional 3,681 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in Pediatrix Medical Group in the second quarter worth $72,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.